IL-8 and IL-1RA serum levels predicting depression treatment response in 6-week follow-up
Acta Neuropsychiatrica · 2025
DOI: 10.1017/neu.2025.10027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropsychiatrica, 2025. Verfasst von Tuukka Mökkönen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. Hauptthemen laut MEDLINE: Major Depressive Disorder, Interleukin-8, Interleukin 1 Receptor Antagonist Protein, Antidepressive Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Objective
This study aims to ascertain the effect of baseline IL-1Ra and IL-8 in the treatment response of patients with major depressive disorder (MDD) and to clarify the relationship between inflammation markers and depression.
Methods
We recruited 242 patients with a Beck Depression Inventory (BDI) score ≥ 17 referred to secondary care in Finland. The patients’ serum IL-1Ra and IL-8 concentrations were measured at baseline. Montgomery-Åsberg Depression Rating Scale (MADRS) tests and Alcohol Use Disorders Identification Tests (AUDIT) were administered at baseline and six weeks. The antidepressant treatments varied: somewere started, others changed or continued their previous medication, and others had their doses adjusted. Patients started behavioral activation therapy. Linear regression was used with a relative MADRS score change during six weeks as the dependent variable and patient age, AUDIT score, BMI, daily number of cigarettes smoked, sex, and serum IL-1Ra and IL-8 concentrations as independent variables.
Results
Higher baseline serum IL-1Ra and IL-8 levels were associated with a smaller relative change in the MADRS-score within the first six weeks of treatment in linear regression analysis ( p < 0.001 and p = 0.007, respectively). In further analysis comparing groups with ≤ 24 and>24 MADRS score only the ≤ 24 MADRS score group showed a similar association.
Conclusion
Higher baseline IL-1Ra and IL-8 concentrations were associated with a lesser relative response to depression treatment, particularly in patients with mild depression. Results on IL-8 concur with earlier findings, whereas the association between higher IL-1Ra serum concentrations reduced treatment response is a novel finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
- Department of Psychiatry, The Pirkanmaa Wellbeing Services County, Tampere, Finland.
- The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
- Department of Psychiatry, Department of Clinical Sciences (Psychiatry), Faculty of Medicine, University Hospital of Umeå, Umeå University, Umeå, Sweden.
- Department of Clinical Medicine (Psychiatry), Faculty of Medicine, University of Turku, Turku, Finland.
- Department of Psychiatry, The Wellbeing Services County of Ostrobothnia, Vaasa, Finland.
ORCID-Profile: Tuukka Mökkönen, Olli Kampman
Zitieren
APA
Mökkönen, T., Solismaa, A., Hämäläinen, M., Moilanen, E., & Kampman, O. (2025). IL-8 and IL-1RA serum levels predicting depression treatment response in 6-week follow-up. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2025.10027
Vancouver
Mökkönen T, Solismaa A, Hämäläinen M, Moilanen E, Kampman O. IL-8 and IL-1RA serum levels predicting depression treatment response in 6-week follow-up. Acta Neuropsychiatrica. 2025. doi:10.1017/neu.2025.10027
BibTeX
@article{Mkknen2025,
author = {Mökkönen, Tuukka and Solismaa, Anssi and Hämäläinen, Mari and Moilanen, Eeva and Kampman, Olli},
title = {IL-8 and IL-1RA serum levels predicting depression treatment response in 6-week follow-up},
journal = {Acta Neuropsychiatrica},
year = {2025},
doi = {10.1017/neu.2025.10027}
}
EUVIMED